
Game-Changing Hope for Ovarian Cancer: Mirvetuximab Emerges as a Lifeline
Mirvetuximab soravtansine-gynx, a new antibody-drug conjugate, offers hope for patients with folate receptor α-positive, platinum-resistant ovarian cancer. Phase 3 MIRASOL trial results show a significant extension in median overall survival to 16.85 months versus 13.34 months with traditional chemotherapy. This treatment reduces